LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer

NCT05886439 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: LK101 injection (personlized neoantigen pulsed DC vaccine )
DRUG: Pembrolizumab
DRUG: Durvalumab
DRUG: Tislelizumab

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences